Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 4Active not recruiting 2Terminated 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 660Carcinoma, Non-Small-Cell Lung 454Prostatic Neoplasms 384Neoplasms 376Lung Neoplasms 261Multiple Myeloma 246Colorectal Neoplasms 231Neoplasm Metastasis 214Melanoma 202Leukemia, Myeloid, Acute 165Ovarian Neoplasms 163Pancreatic Neoplasms 155Carcinoma, Renal Cell 141Squamous Cell Carcinoma of Head and Neck 137Lymphoma 134Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 123Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 117Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 107Stomach Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 100Hematologic Neoplasms 99Lymphoma, Follicular 95Sarcoma 93

Interventions

Solutions 1Everolimus 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Seizures × 1 year × Clear all
NCT05485831 2026-06-03

EpiTALY

Jazz Pharmaceuticals

Active not recruiting
111 enrolled

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡